Literature DB >> 10689518

[Direct autotransfusion systems deliver blood of inadequate quality].

T Rosolski1, K Mauermann, U Frick, M Hergert.   

Abstract

OBJECTIVE: Systems for direct retransfusion of blood salvaged from the surgical field and in drainage systems (direct autotransfusion) have been in use for many years. The quality of the blood obtained with such systems, however, has not been systemically assessed in a comparative manner. The aim of our study was the analysis of the quality of the blood, obtained with three commercially available direct autotransfusion systems (drainage systems with filters).
METHODS: With ethics committee approval and informed consent, 30 patients receiving knee arthroplasty were randomly allocated to three groups. Each group of 10 patients received treatment with one drainage system (Consta Vac, Solcotrans, Haem-o-Trans). In the salvaged blood, we measured cellular elements, variables of coagulation and fibrinolysis, complement activation and cellular elements, both before and after passage of the autotransfusion system.
RESULTS: Analysis revealed a low haematokrit (< 30%) and platelet count (< 80 Gpt/l). The salvaged blood proved uncoagulable and defibrinised with no measurable clotting and fibrinogen; clotting activity, fibrinolysis and complement reaction were grossly induced (TAT, PAP and FDP high, C3 low). The blood was contaminated with cellular debris reflected by concentration of enzymes usually confined to the intracellular space (LDH, elastase, beta-thromboglobulin).
CONCLUSION: The systems/filters assessed in this study do not improve quality of blood drained from the surgical field. Retransfusion of such blood can not be recommended.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10689518     DOI: 10.1055/s-2000-233

Source DB:  PubMed          Journal:  Anasthesiol Intensivmed Notfallmed Schmerzther        ISSN: 0939-2661            Impact factor:   0.698


  1 in total

1.  [Retransfusion of autologous blood].

Authors:  E Hansen
Journal:  Anaesthesist       Date:  2002-05       Impact factor: 1.041

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.